Genprex, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

GNPX$2.09+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

	Year Ended
	December 31,
2025 · 2024
Cash flows from operating activities:
Net loss		$(16,228,953)	$(21,111,163)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		—	6,693
Share-based compensation and issuance of stock for services		312,835	3,302,982
Non cash financing costs		739,935	—
Changes in operating assets and liabilities:
Prepaid expenses and other		(50,120)	328,330
Research and development supplies		244,630	300,630
Accounts payable		(331,226)	(323,315)
Other current liabilities		1,690	(426,723)
Net cash used in operating activities		(15,311,209)	(17,922,566)
Cash flows from investing activities:
Disposals of property and equipment		—	1,166
Reductions to intellectual property		—	773,478
Net cash provided by investing activities		—	774,644
Cash flows from financing activities:
Net proceeds from issuances of common stock		21,540,404	12,011,953
Net cash provided by financing activities		21,540,404	12,011,953
Net increase (decrease) in cash and cash equivalents		6,229,195	(5,135,969)
Cash and cash equivalents, beginning of year		1,601,660	6,737,629
Cash and cash equivalents, end of year		$7,830,855	$1,601,660
Supplemental schedule of non-cash investing and financing activities:
Deemed dividend related to warrant modification	$	-	$(277,119)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.